The FDA has approved Adakveo (crizanlizumab-tmca; Novartis) to reduce the frequency of vaso-occlusive crisis (VOC) in patients aged ≥16 years with sickle cell disease.
Individuals with sickle cell disease were estimated to earn nearly $700,000 less over their lifetime compared with similar individuals without sickle cell disease.
The FDA has approved Reblozyl (luspatercept–aamt; Celgene and Acceleron) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Postoperative anemia was significantly associated with a composite end point of mortality and major ischemic outcomes within 90 days.
Researchers found similar incidences of late events in patients who were treated with and without granulocyte colony-stimulating factor.
Approximately two-thirds of patients who completed a screening questionnaire reported having at least 1 unmet socioeconomic need.
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
More than two-thirds of patients receiving horse antithymocyte globulin plus cyclosporine achieved a very good partial response or better.
Children born to mothers diagnosed with iron-deficiency anemia prior to 30 weeks of gestation were more likely to have a neurodevelopmental disorder.
Nearly two-thirds of ischemic strokes occurred in patients who had not properly completed the STOP protocol.
Low and high hemoglobin levels were associated with increased risk for dementia, white matter hyperintensity volume, and structural connectivity.
In a study of chronic kidney disease patients undergoing vascular access surgery for hemodialysis, severe preoperative anemia was associated with worse outcomes.
Depressive symptoms, spirituality, and missed clinic appointments were all found to correlate with hospital admission in sickle cell disease.
Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
The primary end point was time to readiness for discharge, defined as the difference between the readiness-for-discharge date and time and the start date and time of the first infusion of study drug.
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Study seeks to recruit up to 45 adults with severe sickle cell disease
Patients with chronic anemia demonstrated a decrease in brain white matter volume proportional to anemia severity.
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.
In separate studies, roxadustat showed superiority over placebo at increasing hemoglobin in patients with CKD anemia and demonstrated noninferiority to epoetin in treating anemia in dialysis patients.
Isomaltoside with derisomaltose yielded a more pronounced hematologic response but a similar safety profile compared with iron sucrose.
Priority Review shortens the FDA review time from 10 months to 6 months
Patients presenting at emergency departments were nearly 4 times as likely to be admitted to a hospital as patients presenting at a day hospital.
A study of anemic patients on peritoneal dialysis found that roxadustat maintained target hemoglobin levels even in those who received previous treatment with an erythropoiesis stimulating agent.
A recent study of patients with chronic kidney disease showed that each 1-km increase in the elevation where they live was associated with 33% decreased odds of anemia.
Transfusing red blood cells into cardiac surgery patients only when their hemoglobin levels fall to below 7.5 g/dL does not increase acute kidney injury risk.
Young patients with sickle cell disease underwent dosing schedules guided by analysis of pharmacokinetic data using a population pharmacokinetic model.
Voxelotor may be a safe and efficacious treatment for sickle cell disease, especially at a dosage of 1500 mg/d.
Patients who experienced an iron chelation response had lower transfusion burden and substantial decrease in ferritin values.
Patients demonstrated a 5-year overall survival rate of 86%, with all but 2 patients achieving neutrophil engraftment.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Decreased lymphocyte counts and serum immunoglobulin levels were seen in patients irrespective of ribosomal protein genotype and steroid treatment.
Researchers assessed the predictive value of various laboratory parameters for iron overload in patients with congenital hemolytic anemias.
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.
Of 20 patients who showed response to eltrombopag at 24 weeks, 25% had not shown response at 12 weeks.
A multidisciplinary intervention strategy led to a 61% decrease in hospital stay duration for patients with sickle cell disease and vaso-occlusive pain.
Anemia in patients with atrial fibrillation is associated with major bleeding and lower time in therapeutic range.
Quantitative sensory testing may facilitate objective evaluation of feelings of pain and function in patients with sickle cell disease.
Immune checkpoint inhibitor (ICI) therapy may lead to autoimmune hemolytic anemia (AIHA), but diagnosis of AIHA may not necessitate ICI discontinuation.
Mometasone usage was found to correlate with decreased levels of macrophage markers but not of asthma-related markers.
Infants with sickle cell disease who started hydroxyurea before 12 months of age had better long-term outcomes.
Patients with iron deficiency anemia who were treated with intravenous iron experienced significant changes in parameters measuring coagulability.
Despite deeper understanding of some of the molecular mechanisms underlying Diamond-Blackfan anemia, the search for effective therapies is ongoing.
A set of diagnostic criteria for defining the types of acute pain observed in patients with sickle cell disease was formulated by a multi-institutional panel of experts.
The use of a less toxic conditioning regimen may establish bone marrow transplantation as a preferred therapeutic alternative for adults with sickle cell disease.
Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.
Novartis announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.
A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.
The long-term outcomes of limiting the frequency of red blood cell transfusions in patients with anemia had not previously been described.
Researchers developed a new method to measure single cell red blood cell deformability.
Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.